Evidence map›Paper›PMID 27892934›Full record

ArticleNutrition & diabetes2016

Treatment with FGFR2-IIIc monoclonal antibody suppresses weight gain and adiposity in KKA

K Nonogaki, T Kaji, T Yamazaki, Mari Murakami

Open access · goldAbstract read
In one paragraph

Article in Nutrition & diabetes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

K NonogakiDepartment of Diabetes Technology, Tohoku University Graduate School of Biomedical Engineering, Sendai, Miyagi, Japan.
T KajiDepartment of Diabetes Technology, Tohoku University Graduate School of Biomedical Engineering, Sendai, Miyagi, Japan.
T YamazakiDepartment of Diabetes Technology, Tohoku University Graduate School of Biomedical Engineering, Sendai, Miyagi, Japan.
Mari MurakamiDepartment of Diabetes Technology, Tohoku University Graduate School of Biomedical Engineering, Sendai, Miyagi, Japan.
Tohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expression of β-Kotho, fibroblast growth factor receptor (FGFR)-1c and 2c, which bind FGF21, is decreased in the white adipose tissue of obese mice. The aim of the present study was to determine the role of FGFR2c in the development of obesity and diabetes in KKA

Indexed as

Adipose TissueAnimalsAntibodies, MonoclonalInjections, IntraperitonealMaleMiceMice, Inbred StrainsMice, ObeseReceptor, Fibroblast Growth Factor, Type 2Weight GainAntibodies, MonoclonalFgfr2 protein, mouseReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID27892934
PMCPMC5133360
OpenAlexW2558700178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.